Caspase functions in cell death and disease

Cold Spring Harbor Perspectives in Biology

Volumn 5, Issue 4, 2013, Pages 1-28

  McIlwain, David R ^a,b   Berger, Thorsten ^a   Mak, Tak W ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; TOLL LIKE RECEPTOR;

ANIMAL; APOPTOSIS; CELL DEATH; DIMERIZATION; GENE EXPRESSION REGULATION; HUMAN; INFLAMMATION; INNATE IMMUNITY; METABOLISM; MOUSE; NECROSIS; NEOPLASM; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; CASPASES; CELL DEATH; DIMERIZATION; GENE EXPRESSION REGULATION; HUMANS; IMMUNITY, INNATE; INFLAMMATION; MICE; NECROSIS; NEOPLASMS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 84875985221     PISSN: None     EISSN: 19430264     Source Type: Journal    
DOI: 10.1101/cshperspect.a008656     Document Type: Article

References (266)

1. Acehan D, Jiang X, Morgan DG, Heuser JE, Wang X, Akey CW. 2002. Three-dimensional structure of the apoptosome: Implications for assembly, procaspase-9 binding, and activation. Mol Cell 9: 423-432.
2. Aksentijevich I, Nowak M, Mallah M, Chae JJ, Watford WT, Hofmann SR, Stein L, Russo R, Goldsmith D, Dent P, et al. 2002. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): A new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum 46: 3340-3348.
3. Alam A, Cohen LY, Aouad S, Sekaly RP. 1999. Early activation of caspases during T lymphocyte stimulation results in selective substrate cleavage in nonapoptotic cells. J Exp Med 190: 1879-1890.
4. Alten R, Gram H, Joosten LA, van den Berg WB, Sieper J, Wassenberg S, Burmester G, van Riel P, Diaz-Lorente M, Bruin GJ, et al. 2008. The human anti-IL-1 β monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res Ther 10: R67.
5. Amer A, Franchi L, Kanneganti TD, Body-Malapel M, Ozoren N, Brady G, Meshinchi S, Jagirdar R, Gewirtz A, Akira S, et al. 2006. Regulation of Legionella phagosome maturation and infection through flagellin and host Ipaf. J Biol Chem 281: 35217-35223.
6. Anderson KV, Bokla L, Nusslein-Volhard C. 1985a. Establishment of dorsal-ventral polarity in the Drosophila embryo: The induction of polarity by the Toll gene product. Cell 42: 791-798.
7. Anderson KV, Jurgens G, Nusslein-Volhard C. 1985b. Establishment of dorsal-ventral polarity in the Drosophila embryo: Genetic studies on the role of the Toll gene product. Cell 42: 779-789.
8. Arai J, Katai N, Kuida K, Kikuchi T, Yoshimura N. 2006. Decreased retinal neuronal cell death in caspase-1 knockout mice. Jpn J Ophthalmol 50: 417-425.
9. Baliga BC, Read SH, Kumar S. 2004. The biochemical mechanism of caspase-2 activation. Cell Death Differ 11: 1234-1241.
10. Baskin-Bey ES, Washburn K, Feng S, Oltersdorf T, Shapiro D, Huyghe M, Burgart L, Garrity-Park M, van Vilsteren FG, Oliver LK, et al. 2007. Clinical trial of the pan-caspase inhibitor, IDN-6556, in human liver preservation injury. Am J Transplant 7: 218-225.
11. Beisner DR, Ch'en IL, Kolla RV, Hoffmann A, Hedrick SM. 2005. Cutting edge: Innate immunity conferred by B cells is regulated by caspase-8. J Immunol 175: 3469-3473.
12. Bergeron L, Perez GI, Macdonald G, Shi L, Sun Y, Jurisicova A, Varmuza S, Latham KE, Flaws JA, Salter JC, et al. 1998. Defects in regulation of apoptosis in caspase-2-deficient mice. Genes Dev 12: 1304-1314.
13. Bergsbaken T, Cookson BT. 2007. Macrophage activation redirects yersinia-infected host cell death from apoptosis to caspase-1-dependent pyroptosis. PLoS Pathog 3: e161.
14. Boatright KM, Renatus M, Scott FL, Sperandio S, Shin H, Pedersen IM, Ricci JE, Edris WA, Sutherlin DP, Green DR, et al. 2003. A unified model for apical caspase activation. Mol Cell 11: 529-541.
15. Boatright KM, Deis C, Denault JB, Sutherlin DP, Salvesen GS. 2004. Activation of caspases-8 and -10 by FLIP(L). Biochem J 382: 651-657.
16. Boyden ED, Dietrich WF. 2006. Nalp1b controls mouse macrophage susceptibility to anthrax lethal toxin. Nat Genet 38: 240-244.
17. Brenner D, Mak TW. 2009. Mitochondrial cell death effectors. Curr Opin Cell Biol 21: 871-877.
18. Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, Nuki G, Pavelka K, Rau R, Rozman B, et al. 1998. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 41: 2196-2204.
19. Brydges SD, Mueller JL, McGeough MD, Pena CA, Misaghi A, Gandhi C, Putnam CD, Boyle DL, Firestein GS, Horner AA, et al. 2009. Inflammasome-mediated disease animal models reveal roles for innate but not adaptive immunity. Immunity 30: 875-887.
20. Burns JC. 2002. Commentary: Translation of Dr. Tomisaku Kawasaki's original report of fifty patients in 1967. Pediatr Infect Dis J 21: 993-995.
21. Cailliez M, Garaix F, Rousset-Rouviere C, Bruno D, Kone-Paut I, Sarles J, Chabrol B, Tsimaratos M. 2006. Anakinra is safe and effective in controlling hyperimmunoglobulinaemia D syndrome-associated febrile crisis. J Inherit Metab Dis 29: 763.
22. Cain K, Bratton SB, Cohen GM. 2002. The Apaf-1 apoptosome: A large caspase-activating complex. Biochimie 84: 203-214.
23. Cassel SL, Eisenbarth SC, Iyer SS, Sadler JJ, Colegio OR, Tephly LA, Carter AB, Rothman PB, Flavell RA, Sutterwala FS. 2008. The Nalp3 inflammasome is essential for the development of silicosis. Proc Natl Acad Sci 105: 9035-9040.
24. Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong SA, Letai A. 2006. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 9: 351-365.
25. Chae JJ, Komarow HD, Cheng J, Wood G, Raben N, Liu PP, Kastner DL. 2003. Targeted disruption of pyrin, the FMF protein, causes heightened sensitivity to endotoxin and a defect in macrophage apoptosis. Mol Cell 11: 591-604.
26. Chae JJ, Wood G, Masters SL, Richard K, Park G, Smith BJ, Kastner DL. 2006. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1β production. Proc Natl Acad Sci 103: 9982-9987.
27. Chae JJ, Wood G, Richard K, Jaffe H, Colburn NT, Masters SL, Gumucio DL, Shoham NG, Kastner DL. 2008. The familial Mediterranean fever protein, pyrin, is cleaved by caspase-1 and activates NF-kB through its N-terminal fragment. Blood 112: 1794-1803.
28. Chamaillard M, Hashimoto M, Horie Y, Masumoto J, Qiu S, Saab L, Ogura Y, Kawasaki A, Fukase K, Kusumoto S, et al. 2003. An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acid. Nat Immunol 4: 702-707.
29. Chang DW, Xing Z, Capacio VL, Peter ME, Yang X. 2003. Interdimer processing mechanism of procaspase-8 activation. EMBO J 22: 4132-4142.
30. Chen DJ, Huerta S. 2009. Smac mimetics as new cancer therapeutics. Anticancer Drugs 20: 646-658.
31. Chen K, Zhao H, Hu Z, Wang LE, Zhang W, Sturgis EM, Wei Q. 2008a. CASP3 polymorphisms and risk of squamous cell carcinoma of the head and neck. Clin Cancer Res 14: 6343-6349.
32. Chen NJ, Chio II, Lin WJ, Duncan G, Chau H, Katz D, Huang HL, Pike KA, Hao Z, Su YW, et al. 2008b. Beyond tumor necrosis factor receptor: TRADD signaling in tolllike receptors. Proc Natl Acad Sci 105: 12429-12434.
33. Chun HJ, Zheng L, Ahmad M, Wang J, Speirs CK, Siegel RM, Dale JK, Puck J, Davis J, Hall CG, et al. 2002. Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency. Nature 419: 395-399.
34. Church LD, McDermott MF. 2009. Canakinumab, a fullyhuman mAb against IL-1β for the potential treatment of inflammatory disorders. Curr Opin Mol Ther 11: 81-89.
35. Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, Kremer J, Bear MB, Rich WJ, McCabe D. 2002. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: Results of a twentyfour-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46: 614-624.
36. Cookson BT, Brennan MA. 2001. Pro-inflammatory programmed cell death. Trends Microbiol 9: 113-114.
37. Cox A, Dunning AM, Garcia-Closas M, Balasubramanian S, Reed MW, Pooley KA, Scollen S, Baynes C, Ponder BA, Chanock S, et al. 2007. A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet 39: 352-358.
38. Cronstein BN, Terkeltaub R. 2006. The inflammatory process of gout and its treatment. Arthritis Res Ther 8: S3.
39. D'Amelio M, Cavallucci V, Middei S, Marchetti C, Pacioni S, Ferri A, Diamantini A, De Zio D, Carrara P, Battistini L, et al. 2011. Caspase-3 triggers early synaptic dysfunction in a mouse model of Alzheimer's disease. Nat Neurosci 14: 69-76.
40. Davis BK, Wen H, Ting JP. 2011. The inflammasome NLRs in immunity, inflammation, and associated diseases. Annu Rev Immunol 29: 707-735.
41. de Calignon A, Fox LM, Pitstick R, Carlson GA, Bacskai BJ, Spires-Jones TL, Hyman BT. 2010. Caspase activation precedes and leads to tangles. Nature 464: 1201-1204.
42. Denault JB, Drag M, Salvesen GS, Alves J, Heidt AB, Deveraux Q, Harris JL. 2007. Small molecules not direct activators of caspases. Nat Chem Biol 3: 519; author reply 520.
43. Denecker G, Hoste E, Gilbert B, Hochepied T, Ovaere P, Lippens S, Van den Broecke C, Van Damme P, D'Herde K, Hachem JP, et al. 2007. Caspase-14 protects against epidermal UVB photodamage and water loss. Nat Cell Biol 9: 666-674.
44. Denecker G, Ovaere P, Vandenabeele P, Declercq W. 2008. Caspase-14 reveals its secrets. J Cell Biol 180: 451-458.
45. Dostert C, Petrilli V, Van Bruggen R, Steele C, Mossman BT, Tschopp J. 2008. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 320: 674-677.
46. Drenth JP, Cuisset L, Grateau G, Vasseur C, van de Velde- Visser SD, de Jong JG, Beckmann JS, van der Meer JW, Delpech M, International Hyper-IgD Study Group. 1999. Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. Nat Genet 22: 178-181.
47. Drevlow BE, Lovis R, Haag MA, Sinacore JM, Jacobs C, Blosche C, Landay A, Moreland LW, Pope RM. 1996. Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis. Arthritis Rheum 39: 257-265.
48. Eggert A, Grotzer MA, Zuzak TJ, Wiewrodt BR, Ho R, Ikegaki N, Brodeur GM. 2001. Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. Cancer Res 61: 1314-1319.
49. Faubel S, Ljubanovic D, Reznikov L, Somerset H, Dinarello CA, Edelstein CL. 2004. Caspase-1-deficient mice are protected against cisplatin-induced apoptosis and acute tubular necrosis. Kidney Int 66: 2202-2213.
50. Faustin B, Lartigue L, Bruey JM, Luciano F, Sergienko E, Bailly-Maitre B, Volkmann N, Hanein D, Rouiller I, Reed JC. 2007. Reconstituted NALP1 inflammasome reveals two-step mechanism of caspase-1 activation. Mol Cell 25: 713-724.
51. Feldmann J, Prieur AM, Quartier P, Berquin P, Certain S, Cortis E, Teillac-Hamel D, Fischer A, de Saint Basile G. 2002. Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. Am J Hum Genet 71: 198-203.
52. Feldmeyer L, Keller M, Niklaus G, Hohl D, Werner S, Beer HD. 2007. The inflammasome mediates UVB-induced activation and secretion of interleukin-1β by keratinocytes. Curr Biol 17: 1140-1145.
53. Fernandes-Alnemri T, Yu JW, Datta P, Wu J, Alnemri ES. 2009. AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature 458: 509-513.
54. Fernandes-Alnemri T, Yu JW, Juliana C, Solorzano L, Kang S, Wu J, Datta P, McCormick M, Huang L, Mc-Dermott E, et al. 2010. The AIM2 inflammasome is critical for innate immunity to Francisella tularensis. Nat Immunol 11: 385-393.
55. Filomenko R, Prevotat L, Rebe C, Cortier M, Jeannin JF, Solary E, Bettaieb A. 2006. Caspase-10 involvement in cytotoxic drug-induced apoptosis of tumor cells. Oncogene 25: 7635-7645.
56. Finckh A, Gabay C. 2008. At the horizon of innovative therapy in rheumatology: New biologic agents. Curr Opin Rheumatol 20: 269-275.
57. Fink SL, Cookson BT. 2006. Caspase-1-dependent pore formation during pyroptosis leads to osmotic lysis of infected host macrophages. Cell Microbiol 8: 1812-1825.
58. Fischer U, Schulze-Osthoff K. 2005. New approaches and therapeutics targeting apoptosis in disease. Pharmacol Rev 57: 187-215.
59. Fischer H, Koenig U, Eckhart L, Tschachler E. 2002. Human caspase 12 has acquired deleterious mutations. Biochem Biophys Res Commun 293: 722-726.
60. Fleisher TA. 2008. The autoimmune lymphoproliferative syndrome: An experiment of nature involving lymphocyte apoptosis. Immunol Res 40: 87-92.
61. Franchi L, Amer A, Body-Malapel M, Kanneganti TD, Ozoren N, Jagirdar R, Inohara N, Vandenabeele P, Bertin J, Coyle A, et al. 2006. Cytosolic flagellin requires Ipaf for activation of caspase-1 and interleukin 1β in salmonellainfected macrophages. Nat Immunol 7: 576-582.
62. Franchi L, Stoolman J, Kanneganti TD, Verma A, Ramphal R, Nunez G. 2007. Critical role for Ipaf in Pseudomonas aeruginosa-induced caspase-1 activation. Eur J Immunol 37: 3030-3039.
63. Frank B, Bermejo JL, Hemminki K, Klaes R, Bugert P, Wappenschmidt B, Schmutzler RK, Burwinkel B. 2005. Re: Association of a common variant of the CASP8 gene with reduced risk of breast cancer. J Natl Cancer Inst 97: 1012; author reply 1012-1013.
64. Frantz S, Ducharme A, Sawyer D, Rohde LE, Kobzik L, Fukazawa R, Tracey D, Allen H, Lee RT, Kelly RA. 2003. Targeted deletion of caspase-1 reduces early mortality and left ventricular dilatation following myocardial infarction. J Mol Cell Cardiol 35: 685-694.
65. Gabay C, Lamacchia C, Palmer G. 2010. IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol 6: 232-241.
66. Genovese MC, Cohen S, Moreland L, Lium D, Robbins S, Newmark R, Bekker P. 2004. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 50: 1412-1419.
67. Girardin SE, Boneca IG, Carneiro LA, Antignac A, Jehanno M, Viala J, Tedin K, Taha MK, Labigne A, Zahringer U, et al. 2003a. Nod1 detects a unique muropeptide from gram-negative bacterial peptidoglycan. Science 300: 1584-1587.
68. Girardin SE, Boneca IG, Viala J, Chamaillard M, Labigne A, Thomas G, Philpott DJ, Sansonetti PJ. 2003b. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 278: 8869-8872.
69. Goldbach-Mansky R, Dailey NJ, Canna SW, Gelabert A, Jones J, Rubin BI, Kim HJ, Brewer C, Zalewski C, Wiggs E, et al. 2006. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1β inhibition. N Engl J Med 355: 581-592.
70. Goldbach-Mansky R, Shroff SD, Wilson M, Snyder C, Plehn S, Barham B, Pham TH, Pucino F, Wesley RA, Papadopoulos JH, et al. 2008. A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum 58: 2432-2442.
71. Gross O, Poeck H, Bscheider M, Dostert C, Hannesschlager N, Endres S, Hartmann G, Tardivel A, Schweighoffer E, Tybulewicz V, et al. 2009. Syk kinase signalling couples to the Nlrp3 inflammasome for anti-fungal host defence. Nature 459: 433-436.
72. Guegan C, Vila M, Teismann P, Chen C, Onteniente B, Li M, Friedlander RM, Przedborski S. 2002. Instrumental activation of bid by caspase-1 in a transgenic mouse model of ALS. Mol Cell Neurosci 20: 553-562.
73. Hakem R, Hakem A, Duncan GS, Henderson JT, Woo M, Soengas MS, Elia A, de la Pompa JL, Kagi D, Khoo W, et al. 1998. Differential requirement for caspase 9 in apoptotic pathways in vivo. Cell 94: 339-352.
74. Halle A, Hornung V, Petzold GC, Stewart CR, Monks BG, Reinheckel T, Fitzgerald KA, Latz E, Moore KJ, Golenbock DT. 2008. The NALP3 inflammasome is involved in the innate immune response to amyloid-β. Nat Immunol 9: 857-865.
75. Hao Z, Duncan GS, Chang CC, Elia A, Fang M, Wakeham A, Okada H, Calzascia T, Jang Y, You-Ten A, et al. 2005. Specific ablation of the apoptotic functions of cytochrome c reveals a differential requirement for cytochrome c and Apaf-1 in apoptosis. Cell 121: 579-591.
76. Harvey NL, Butt AJ, Kumar S. 1997. Functional activation of Nedd2/ICH-1 (caspase-2) is an early process in apoptosis. J Biol Chem 272: 13134-13139.
77. Hawkins PN, Lachmann HJ, McDermott MF. 2003. Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N Engl J Med 348: 2583-2584.
78. Hawkins PN, Bybee A, Aganna E, McDermott MF. 2004a. Response to anakinra in a de novo case of neonatal-onset multisystem inflammatory disease. Arthritis Rheum 50: 2708-2709.
79. Hawkins PN, Lachmann HJ, Aganna E, McDermott MF. 2004b. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum 50: 607-612.
80. Herzyk DJ, Allen JN, Marsh CB, Wewers MD. 1992. Macrophage and monocyte IL-1β regulation differs at multiple sites. Messenger RNA expression, translation, and posttranslational processing. J Immunol 149: 3052-3058.
81. Ho LH, Taylor R, Dorstyn L, Cakouros D, Bouillet P, Kumar S. 2009. A tumor suppressor function for caspase-2. Proc Natl Acad Sci 106: 5336-5341.
82. Hoffman HM. 2009. Rilonacept for the treatment of cryopyrin-associated periodic syndromes (CAPS). Expert Opin Biol Ther 9: 519-531.
83. Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD. 2001. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 29: 301-305.
84. Hoffman HM, Rosengren S, Boyle DL, Cho JY, Nayar J, Mueller JL, Anderson JP, Wanderer AA, Firestein GS. 2004. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 364: 1779-1785.
85. Hoffman HM, Throne ML, Amar NJ, Sebai M, Kivitz AJ, Kavanaugh A, Weinstein SP, Belomestnov P, Yancopoulos GD, Stahl N, et al. 2008. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: Results from two sequential placebo-controlled studies. Arthritis Rheum 58: 2443-2452.
86. Hopkins-Donaldson S, Bodmer JL, Bourloud KB, Brognara CB, Tschopp J, Gross N. 2000. Loss of caspase-8 expression in highly malignant human neuroblastoma cells correlates with resistance to tumor necrosis factorrelated apoptosis-inducing ligand-induced apoptosis. Cancer Res 60: 4315-4319.
87. Hornung V, Bauernfeind F, Halle A, Samstad EO, Kono H, Rock KL, Fitzgerald KA, Latz E. 2008. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 9: 847-856.
88. Hornung V, Ablasser A, Charrel-Dennis M, Bauernfeind F, Horvath G, Caffrey DR, Latz E, Fitzgerald KA. 2009. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature 458: 514- 518.
89. Hosgood HD 3rd, Baris D, Zhang Y, Zhu Y, Zheng T, Yeager M, Welch R, Zahm S, Chanock S, Rothman N, et al. 2008. Caspase polymorphisms and genetic susceptibility to multiple myeloma. Hematol Oncol 26: 148-151.
90. Houten SM, Kuis W, Duran M, de Koning TJ, van Royen-Kerkhof A, Romeijn GJ, Frenkel J, Dorland L, de Barse MM, Huijbers WA, et al. 1999. Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinaemia D and periodic fever syndrome. Nat Genet 22: 175-177.
91. Hsu LC, Ali SR, McGillivray S, Tseng PH, Mariathasan S, Humke EW, Eckmann L, Powell JJ, Nizet V, Dixit VM, et al. 2008. A NOD2-NALP1 complex mediates caspase-1-dependent IL-1β secretion in response to Bacillus anthracis infection and muramyl dipeptide. Proc Natl Acad Sci 105: 7803-7808.
92. Hu B, Elinav E, Huber S, Booth CJ, Strowig T, Jin C, Eisenbarth SC, Flavell RA. 2010. Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4. Proc Natl Acad Sci 107: 21635-21640.
93. Inohara N, Ogura Y, Fontalba A, Gutierrez O, Pons F, Crespo J, Fukase K, Inamura S, Kusumoto S, Hashimoto M, et al. 2003. Host recognition of bacterial mur amyl dipeptide mediated through NOD2. Implications for Crohn's disease. J Biol Chem 278: 5509-5512.
94. Jang JS, Kim KM, Choi JE, Cha SI, Kim CH, Lee WK, Kam S, Jung TH, Park JY. 2008. Identification of polymorphisms in the Caspase-3 gene and their association with lung cancer risk. Mol Carcinog 47: 383-390.
95. Jiang Y, Genant HK, Watt I, Cobby M, Bresnihan B, Aitchison R, McCabe D. 2000. A multicenter, doubleblind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: Radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 43: 1001-1009.
96. Jiang X, Kim HE, Shu H, Zhao Y, Zhang H, Kofron J, Donnelly J, Burns D, Ng SC, Rosenberg S, et al. 2003. Distinctive roles of PHAP proteins and prothymosin-α in a death regulatory pathway. Science 299: 223-226.
97. Jin C, Flavell RA. 2010. Molecular mechanism of NLRP3 inflammasome activation. J Clin Immunol 30: 628-631.
98. Jones JD, Dangl JL. 2006. The plant immune system. Nature 444: 323-329.
99. Jost PJ, Grabow S, Gray D, McKenzie MD, Nachbur U, Huang DC, Bouillet P, Thomas HE, Borner C, Silke J, et al. 2009. XIAP discriminates between type I and type II FAS-induced apoptosis. Nature 460: 1035-1039.
100. Juo P, Kuo CJ, Yuan J, Blenis J. 1998. Essential requirement for caspase-8/FLICE in the initiation of the Fas-induced apoptotic cascade. Curr Biol 8: 1001-1008.
101. Kaiser WJ, Upton JW, Long AB, Livingston-Rosanoff D, Daley-Bauer LP, Hakem R, Caspary T, Mocarski ES. 2011. RIP3 mediates the embryonic lethality of caspase-8-deficient mice. Nature 471: 368-372.
102. Kalliolias GD, Liossis SN. 2008. The future of the IL-1 receptor antagonist anakinra: From rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis. Expert Opin Investig Drugs 17: 349- 359.
103. Kang TB, Ben-Moshe T, Varfolomeev EE, Pewzner-Jung Y, Yogev N, Jurewicz A, Waisman A, Brenner O, Haffner R, Gustafsson E, et al. 2004. Caspase-8 serves both apoptotic and nonapoptotic roles. J Immunol 173: 2976-2984.
104. Kanneganti TD, Body-Malapel M, Amer A, Park JH, Whitfield J, Franchi L, Taraporewala ZF, Miller D, Patton JT, Inohara N, et al. 2006. Critical role for Cryopyrin/Nalp3 in activation of caspase-1 in response to viral infection and double-stranded RNA. J Biol Chem 281: 36560- 36568.
105. Kawasaki T. 1967. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Arerugi 16: 178-222.
106. Kayagaki N, Warming S, Lamkanfi M, Vande Walle L, Louie S, Dong J, Newton K, Qu Y, Liu J, Heldens S, et al. 2011. Non-canonical inflammasome activation targets caspase-11. Nature 479: 117-121.
107. Kelly A, Ramanan AV. 2008. A case of macrophage activation syndrome successfully treated with anakinra. Nat Clin Pract Rheumatol 4: 615-620.
108. Kelly JL, Novak AJ, Fredericksen ZS, Liebow M, Ansell SM, Dogan A, Wang AH, Witzig TE, Call TG, Kay NE, et al. 2010. Germline variation in apoptosis pathway genes and risk of non-Hodgkin's lymphoma. Cancer Epidemiol Biomarkers Prev 19: 2847-2858.
109. Kennedy NJ, Kataoka T, Tschopp J, Budd RC. 1999. Caspase activation is required for T cell proliferation. J Exp Med 190: 1891-1896.
110. Kim HS, Lee JW, Soung YH, Park WS, Kim SY, Lee JH, Park JY, Cho YG, Kim CJ, Jeong SW, et al. 2003. Inactivating mutations of caspase-8 gene in colorectal carcinomas. Gastroenterology 125: 708-715.
111. Kim MS, Oh JE, Min CK, Lee S, Chung NG, Yoo NJ, Lee SH. 2009. Mutational analysis of CASP10 gene in acute leukaemias and multiple myelomas. Pathology 41: 484-487.
112. Kischkel FC, Lawrence DA, Tinel A, LeBlanc H, Virmani A, Schow P, Gazdar A, Blenis J, Arnott D, Ashkenazi A. 2001. Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J Biol Chem 276: 46639-46646.
113. Knoblach SM, Alroy DA, Nikolaeva M, Cernak I, Stoica BA, Faden AI. 2004. Caspase inhibitor z-DEVD-fmk attenuates calpain and necrotic cell death in vitro and after traumatic brain injury. J Cereb Blood Flow Metab 24: 1119-1132.
114. Kolodgie FD, Narula J, Burke AP, Haider N, Farb A, Hui-Liang Y, Smialek J, Virmani R. 2000. Localization of apoptotic macrophages at the site of plaque rupture in sudden coronary death. Am J Pathol 157: 1259-1268.
115. Kovalenko A, Kim JC, Kang TB, Rajput A, Bogdanov K, Dittrich-Breiholz O, Kracht M, Brenner O, Wallach D. 2009. Caspase-8 deficiency in epidermal keratinocytes triggers an inflammatory skin disease. J Exp Med 206: 2161-2177.
116. Krumschnabel G, Manzl C, Villunger A. 2009. Caspase-2: Killer, savior and safeguard-Emerging versatile roles for an ill-defined caspase. Oncogene 28: 3093-3096.
117. Kufer TA, Fritz JH, Philpott DJ. 2005. NACHT-LRR proteins (NLRs) in bacterial infection and immunity. Trends Microbiol 13: 381-388.
118. Kuida K, Lippke JA, Ku G, Harding MW, Livingston DJ, Su MS, Flavell RA. 1995. Altered cytokine export and apoptosis in mice deficient in interleukin-1β converting enzyme. Science 267: 2000-2003.
119. Kuida K, Zheng TS, Na S, Kuan C, Yang D, Karasuyama H, Rakic P, Flavell RA. 1996. Decreased apoptosis in the brain and premature lethality in CPP32-deficient mice. Nature 384: 368-372.
120. Kuida K, Haydar TF, Kuan CY, Gu Y, Taya C, Karasuyama H, Su MS, Rakic P, Flavell RA. 1998. Reduced apoptosis and cytochrome c-mediated caspase activation in mice lacking caspase 9. Cell 94: 325-337.
121. Kuijk LM, Beekman JM, Koster J, Waterham HR, Frenkel J, Coffer PJ. 2008. HMG-CoA reductase inhibition induces IL-1β release through Rac1/PI3K/PKB-dependent caspase-1 activation. Blood 112: 3563-3573.
122. Kumar S, Kinoshita M, Noda M, Copeland NG, Jenkins NA. 1994. Induction of apoptosis by the mouse Nedd2 gene, which encodes a protein similar to the product of the Caenorhabditis elegans cell death gene ced-3 and the mammalian IL-1 β-converting enzyme. Genes Dev 8: 1613-1626.
123. Kuo HC, Yu HR, Juo SH, Yang KD, Wang YS, Liang CD, Chen WC, Chang WP, Huang CF, Lee CP, et al. 2011. CASP3 gene single-nucleotide polymorphism (rs72689236) and Kawasaki disease in Taiwanese children. J Hum Genet 56: 161-165.
124. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, Leslie KS, Hachulla E, Quartier P, Gitton X, Widmer A, Patel N, Hawkins PN. 2009a. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 360: 2416-2425.
125. Lachmann HJ, Lowe P, Felix SD, Rordorf C, Leslie K, Madhoo S, Wittkowski H, Bek S, Hartmann N, Bosset S, et al. 2009b. In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes. J Exp Med 206: 1029-1036.
126. Lafont E, Milhas D, Teissie J, Therville N, Andrieu-Abadie N, Levade T, Benoist H, Segui B. 2010. Caspase-10-dependent cell death in Fas/CD95 signalling is not abrogated by caspase inhibitor zVAD-fmk. PLoS ONE 5: e13638.
127. Lakhani SA, Masud A, Kuida K, Porter GA Jr, Booth CJ, Mehal WZ, Inayat I, Flavell RA. 2006. Caspases 3 and 7: Key mediators of mitochondrial events of apoptosis. Science 311: 847-851.
128. Lamkanfi M, Declercq W, Kalai M, Saelens X, Vandenabeele P. 2002. Alice in caspase land. A phylogenetic analysis of caspases from worm to man. Cell Death Differ 9: 358-361.
129. Lan Q, Zheng T, Chanock S, Zhang Y, Shen M, Wang SS, Berndt SI, Zahm SH, Holford TR, Leaderer B, et al. 2007. Genetic variants in caspase genes and susceptibility to non-Hodgkin lymphoma. Carcinogenesis 28: 823-827.
130. Lan Q, Morton LM, Armstrong B, Hartge P, Menashe I, Zheng T, Purdue MP, Cerhan JR, Zhang Y, Grulich A, et al. 2009. Genetic variation in caspase genes and risk of non-Hodgkin lymphoma: A pooled analysis of 3 population-based case-control studies. Blood 114: 264-267.
131. Larsen CM, Faulenbach M, Vaag A, Volund A, Ehses JA, Seifert B, Mandrup-Poulsen T, Donath MY. 2007. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 356: 1517-1526.
132. Larsen CM, Faulenbach M, Vaag A, Ehses JA, Donath MY, Mandrup-Poulsen T. 2009. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 32: 1663-1668.
133. Lee JW, Kim MR, Soung YH, Nam SW, Kim SH, Lee JY, Yoo NJ, Lee SH. 2006. Mutational analysis of the CASP6 gene in colorectal and gastric carcinomas. APMIS 114: 646-650.
134. Lee HJ, Pyo JO, Oh Y, Kim HJ, Hong SH, Jeon YJ, Kim H, Cho DH, Woo HN, Song S, et al. 2007. AK2 activates a novel apoptotic pathway through formation of a complex with FADD and caspase-10. Nat Cell Biol 9: 1303-1310.
135. Lee P, Lee DJ, Chan C, Chen SW, Ch'en I, Jamora C. 2009a. Dynamic expression of epidermal caspase 8 simulates a wound healing response. Nature 458: 519-523.
136. Lee WK, Kim JS, Kang HG, Cha SI, Kim DS, Hyun DS, Kam S, Kim CH, Jung TH, Park JY. 2009b. Polymorphisms in the Caspase7 gene and the risk of lung cancer. Lung Cancer 65: 19-24.
137. Lenardo M, Chan KM, Hornung F, McFarland H, Siegel R, Wang J, Zheng L. 1999. Mature T lymphocyte apoptosis-Immune regulation in a dynamic and unpredictable antigenic environment. Annu Rev Immunol 17: 221-253.
138. Lens SM, Kataoka T, Fortner KA, Tinel A, Ferrero I, MacDonald RH, Hahne M, Beermann F, Attinger A, Orbea HA, et al. 2002. The caspase 8 inhibitor c-FLIP(L) modulates T-cell receptor-induced proliferation but not activation-induced cell death of lymphocytes. Mol Cell Biol 22: 5419-5433.
139. Lequerre T, Quartier P, Rosellini D, Alaoui F, De Bandt M, Mejjad O, Kone-Paut I, Michel M, Dernis E, Khellaf M, et al. 2008. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: Preliminary experience in France. Ann Rheum Dis 67: 302-308.
140. Li P, Allen H, Banerjee S, Franklin S, Herzog L, Johnston C, McDowell J, Paskind M, Rodman L, Salfeld J, et al. 1995. Mice deficient in IL-1β-converting enzyme are defective in production of mature IL-1β and resistant to endotoxic shock. Cell 80: 401-411.
141. Li J, Brieher WM, Scimone ML, Kang SJ, Zhu H, Yin H, von Andrian UH, Mitchison T, Yuan J. 2007. Caspase-11 regulates cell migration by promoting Aip1-Cofilin-mediated actin depolymerization. Nat Cell Biol 9: 276-286.
142. Li C, Lasse S, Lee P, Nakasaki M, Chen SW, Yamasaki K, Gallo RL, Jamora C. 2010. Development of atopic dermatitis-like skin disease from the chronic loss of epidermal caspase-8. Proc Natl Acad Sci 107: 22249-22254.
143. Lightfield KL, Persson J, Trinidad NJ, Brubaker SW, Kofoed EM, Sauer JD, Dunipace EA, Warren SE, Miao EA, Vance RE. 2011. Differential requirements for NAIP5 in activation of the NLRC4 (IPAF) inflammasome. Infect Immun 79: 1606-1614.
144. Liu XH, Kwon D, Schielke GP, Yang GY, Silverstein FS, Barks JD. 1999. Mice deficient in interleukin-1 converting enzyme are resistant to neonatal hypoxic-ischemic brain damage. J Cereb Blood Flow Metab 19: 1099-1108.
145. Loo YM, Gale M Jr. 2011. Immune signaling by RIG-I-like receptors. Immunity 34: 680-692.
146. Ludlow LE, Johnstone RW, Clarke CJ. 2005. The HIN-200 family: More than interferon-inducible genes? Exp Cell Res 308: 1-17.
147. MacPherson G, Healey CS, Teare MD, Balasubramanian SP, Reed MW, Pharoah PD, Ponder BA, Meuth M, Bhattacharyya NP, Cox A. 2004. Association of a common variant of the CASP8 gene with reduced risk of breast cancer. J Natl Cancer Inst 96: 1866-1869.
148. Madden SD, Cotter TG. 2008. Cell death in brain development and degeneration: Control of caspase expression may be key! Mol Neurobiol 37: 1-6.
149. Maedler K, Dharmadhikari G, Schumann DM, Storling J. 2009. Interleukin-1β targeted therapy for type 2 diabetes. Expert Opin Biol Ther 9: 1177-1188.
150. Mandey SH, Kuijk LM, Frenkel J, Waterham HR. 2006. A role for geranylgeranylation in interleukin-1β secretion. Arthritis Rheum 54: 3690-3695.
151. Manns EL, Hoepelman AIM, Choi HJ, Lee JY, Cornpropst M, Liang W, King B, Hirsch KR, Oldach D, Rousseau FS. 2010. Short term safety, tolerability, pharmacokinetics and preliminary activity of GS 9450, a selective caspase inhibitor, in patients with chronic HCV infection. In 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010), Vienna, Austria.
152. Mariathasan S, Newton K, Monack DM, Vucic D, French DM, Lee WP, Roose-Girma M, Erickson S, Dixit VM. 2004. Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature 430: 213-218.
153. Mariathasan S, Weiss DS, Newton K, McBride J, O'Rourke K, Roose-Girma M, Lee WP, Weinrauch Y, Monack DM, Dixit VM. 2006. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440: 228-232.
154. Martinon F, Burns K, Tschopp J. 2002. The inflammasome: A molecular platform triggering activation of inflammatory caspases and processing of proIL-β. Mol Cell 10: 417-426.
155. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. 2006. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440: 237-241.
156. McGonagle D, Tan AL, Shankaranarayana S, Madden J, Emery P, McDermott MF. 2007. Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra. Ann Rheum Dis 66: 1683- 1684.
157. McGonagle D, Tan AL, Madden J, Emery P, McDermott MF. 2008. Successful treatment of resistant pseudogout with anakinra. Arthritis Rheum 58: 631-633.
158. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. 1997. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388: 394-397.
159. Meng G, Zhang F, Fuss I, Kitani A, Strober W. 2009. A mutation in the Nlrp3 gene causing inflammasome hyperactivation potentiates Th17 cell-dominant immune responses. Immunity 30: 860-874.
160. Merkle S, Frantz S, Schon MP, Bauersachs J, Buitrago M, Frost RJ, Schmitteckert EM, Lohse MJ, Engelhardt S. 2007. A role for caspase-1 in heart failure. Circ Res 100: 645-653.
161. Miao EA, Alpuche-Aranda CM, Dors M, Clark AE, Bader MW, Miller SI, Aderem A. 2006. Cytoplasmic flagellin activates caspase-1 and secretion of interleukin 1β via Ipaf. Nat Immunol 7: 569-575.
162. Miao EA, Ernst RK, Dors M, Mao DP, Aderem A. 2008. Pseudomonas aeruginosa activates caspase 1 through Ipaf. Proc Natl Acad Sci 105: 2562-2567.
163. Miao EA, Mao DP, Yudkovsky N, Bonneau R, Lorang CG, Warren SE, Leaf IA, Aderem A. 2010. Innate immune detection of the type III secretion apparatus through the NLRC4 inflammasome. Proc Natl Acad Sci 107: 3076-3080.
164. Molofsky AB, Byrne BG, Whitfield NN, Madigan CA, Fuse ET, Tateda K, Swanson MS. 2006. Cytosolic recognition of flagellin by mouse macrophages restricts Legionella pneumophila infection. J Exp Med 203: 1093- 1104.
165. Monie TP, Bryant CE, Gay NJ. 2009. Activating immunity: Lessons from the TLRs and NLRs. Trends Biochem Sci 34: 553-561.
166. Muruve DA, Petrilli V, Zaiss AK, White LR, Clark SA, Ross PJ, Parks RJ, Tschopp J. 2008. The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature 452: 103-107.
167. Muzio M, Stockwell BR, Stennicke HR, Salvesen GS, Dixit VM. 1998. An induced proximity model for caspase-8 activation. J Biol Chem 273: 2926-2930.
168. Nakagawa T, Zhu H, Morishima N, Li E, Xu J, Yankner BA, Yuan J. 2000. Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-β. Nature 403: 98-103.
169. Netea MG, van de Veerdonk FL, Kullberg BJ, Van der Meer JW, Joosten LA. 2008. The role of NLRs and TLRs in the activation of the inflammasome. Expert Opin Biol Ther 8: 1867-1872.
170. Oberst A, Green DR. 2011. It cuts both ways: Reconciling the dual roles of caspase 8 in cell death and survival. Nat Rev Mol Cell Biol 12: 757-763.
171. Oberst A, Dillon CP, Weinlich R, McCormick LL, Fitzgerald P, Pop C, Hakem R, Salvesen GS, Green DR. 2011. Catalytic activity of the caspase-8-FLIP(L) complex inhibits RIPK3-dependent necrosis. Nature 471: 363- 367.
172. O'Brien RJ, Wong PC. 2011. Amyloid precursor protein processing and Alzheimer's disease. Ann Rev Neurosci 34: 185-204.
173. Oh JE, Kim MS, Ahn CH, Kim SS, Han JY, Lee SH, Yoo NJ. 2010. Mutational analysis of CASP10 gene in colon, breast, lung and hepatocellular carcinomas. Pathology 42: 73-76.
174. Olson NE, Graves JD, Shu GL, Ryan EJ, Clark EA. 2003. Caspase activity is required for stimulated B lymphocytes to enter the cell cycle. J Immunol 170: 6065-6072.
175. Olsson M, Vakifahmetoglu H, Abruzzo PM, Hogstrand K, Grandien A, Zhivotovsky B. 2009. DISC-mediated activation of caspase-2 in DNA damage-induced apoptosis. Oncogene 28: 1949-1959.
176. Onouchi Y, Ozaki K, Buns JC, Shimizu C, Hamada H, Honda T, Terai M, Honda A, Takeuchi T, Shibuta S, et al. 2010. Common variants in CASP3 confer susceptibility to Kawasaki disease. Hum Mol Genet 19: 2898- 2906.
177. O'Reilly LA, Ekert P, Harvey N, Marsden V, Cullen L, Vaux DL, Hacker G, Magnusson C, Pakusch M, Cecconi F, et al. 2002. Caspase-2 is not required for thymocyte or neuronal apoptosis even though cleavage of caspase-2 is dependent on both Apaf-1 and caspase-9. Cell Death Differ 9: 832-841.
178. Osorio F, Reis ESC. 2011. Myeloid C-type lectin receptors in pathogen recognition and host defense. Immunity 34: 651-664.
179. Papin S, Cuenin S, Agostini L, Martinon F, Werner S, Beer HD, Grutter C, Grutter M, Tschopp J. 2007. The SPRY domain of Pyrin, mutated in familial Mediterranean fever patients, interacts with inflammasome components and inhibits proIL-1β processing. Cell Death Differ 14: 1457-1466.
180. Park HH, Wu H. 2006. Crystal structure of RAIDD death domain implicates potential mechanism of PIDDosome assembly. J Mol Biol 357: 358-364.
181. Park WS, Lee JH, Shin MS, Park JY, Kim HS, Kim YS, Lee SN, Xiao W, Park CH, Lee SH, et al. 2002. Inactivating mutations of the caspase-10 gene in gastric cancer. Oncogene 21: 2919-2925.
182. Park SJ, Wu CH, Gordon JD, Zhong X, Emami A, Safa AR. 2004. Taxol induces caspase-10-dependent apoptosis. J Biol Chem 279: 51057-51067.
183. Park JY, Park JM, Jang JS, Choi JE, Kim KM, Cha SI, Kim CH, Kang YM, Lee WK, Kam S, et al. 2006. Caspase 9 promoter polymorphisms and risk of primary lung cancer. Hum Mol Genet 15: 1963-1971.
184. Park HH, Logette E, Raunser S, Cuenin S, Walz T, Tschopp J, Wu H. 2007. Death domain assembly mechanism revealed by crystal structure of the oligomeric PIDDosome core complex. Cell 128: 533-546.
185. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. 2005. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 201: 1479-1486.
186. Peterson QP, Hsu DC, Goode DR, Novotny CJ, Totten RK, Hergenrother PJ. 2009. Procaspase-3 activation as an anti-cancer strategy: Structure-activity relationship of procaspase-activating compound 1 (PAC-1) and its cellular co-localization with caspase-3. J Med Chem 52: 5721-5731.
187. Peterson QP, Hsu DC, Novotny CJ, West DC, Kim D, Schmit JM, Dirikolu L, Hergenrother PJ, Fan TM. 2010. Discovery and canine preclinical assessment of a nontoxic procaspase-3-activating compound. Cancer Res 70: 7232-7241.
188. Philchenkov A, Zavelevich M, Kroczak TJ, Los M. 2004. Caspases and cancer: Mechanisms of inactivation and new treatment modalities. Exp Oncol 26: 82-97.
189. Poyet JL, Srinivasula SM, Tnani M, Razmara M, Fernandes-Alnemri T, Alnemri ES. 2001. Identification of Ipaf, a human caspase-1-activating protein related to Apaf-1. J Biol Chem 276: 28309-28313.
190. Putt KS, Chen GW, Pearson JM, Sandhorst JS, Hoagland MS, Kwon JT, Hwang SK, Jin H, Churchwell MI, Cho MH, et al. 2006. Small-molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy. Nat Chem Biol 2: 543-550.
191. Rathinam VA, Jiang Z, Waggoner SN, Sharma S, Cole LE, Waggoner L, Vanaja SK, Monks BG, Ganesan S, Latz E, et al. 2010. The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses. Nat Immunol 11: 395-402.
192. Renolleau S, Fau S, Goyenvalle C, Joly LM, Chauvier D, Jacotot E, Mariani J, Charriaut-Marlangue C. 2007. Specific caspase inhibitor Q-VD-OPh prevents neonatal stroke in P7 rat: A role for gender. J Neurochem 100: 1062-1071.
193. Riedl SJ, Shi Y. 2004. Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol 5: 897-907.
194. Rohn TT, Head E. 2009. Caspases as therapeutic targets in Alzheimer's disease: Is it time to "cut" to the chase? Int J Clin Exp Pathol 2: 108-118.
195. Rohn TT, Head E, Su JH, Anderson AJ, Bahr BA, Cotman CW, Cribbs DH. 2001. Correlation between caspase activation and neurofibrillary tangle formation in Alzheimer's disease. Am J Pathol 158: 189-198.
196. Roldan R, Ruiz AM, Miranda MD, Collantes E. 2008. Anakinra: New therapeutic approach in children with Familial Mediterranean Fever resistant to colchicine. Joint Bone Spine 75: 504-505.
197. Roy S, Bayly CI, Gareau Y, Houtzager VM, Kargman S, Keen SL, Rowland K, Seiden IM, Thornberry NA, Nicholson DW. 2001. Maintenance of caspase-3 proenzyme dormancy by an intrinsic "safety catch" regulatory tripeptide. Proc Natl Acad Sci 98: 6132-6137.
198. Saleh M, Vaillancourt JP, Graham RK, Huyck M, Srinivasula SM, Alnemri ES, Steinberg MH, Nolan V, Baldwin CT, Hotchkiss RS, et al. 2004. Differential modulation of endotoxin responsiveness by human caspase-12 polymorphisms. Nature 429: 75-79.
199. Saleh M, Mathison JC, Wolinski MK, Bensinger SJ, Fitzgerald P, Droin N, Ulevitch RJ, Green DR, Nicholson DW. 2006. Enhanced bacterial clearance and sepsis resistance in caspase-12-deficient mice. Nature 440: 1064-1068.
200. Salmena L, Lemmers B, Hakem A, Matysiak-Zablocki E, Murakami K, Au PY, Berry DM, Tamblyn L, Shehabeldin A, Migon E, et al. 2003. Essential role for caspase 8 in T-cell homeostasis and T-cell-mediated immunity. Genes Dev 17: 883-895.
201. Samraj AK, Keil E, Ueffing N, Schulze-Osthoff K, Schmitz I. 2006. Loss of caspase-9 provides genetic evidence for the type I/II concept of CD95-mediated apoptosis. J Biol Chem 281: 29652-29659.
202. Schroder K, Tschopp J. 2010. The inflammasomes. Cell 140: 821-832.
203. Scott AM, Saleh M. 2007. The inflammatory caspases: Guardians against infections and sepsis. Cell Death Differ 14: 23-31.
204. Seshadri S, Duncan MD, Hart JM, Gavrilin MA, Wewers MD. 2007. Pyrin levels in human monocytes and monocyte-derived macrophages regulate IL-1β processing and release. J Immunol 179: 1274-1281.
205. Shi L, Chen G, MacDonald G, Bergeron L, Li H, Miura M, Rotello RJ, Miller DK, Li P, Seshadri T, et al. 1996. Activation of an interleukin 1 converting enzyme-dependent apoptosis pathway by granzyme B. Proc Natl Acad Sci 93: 11002-11007.
206. Shi M, Vivian CJ, Lee KJ, Ge C, Morotomi-Yano K, Manzl C, Bock F, Sato S, Tomomori-Sato C, Zhu R, et al. 2009. DNA-PKcs-PIDDosome: A nuclear caspase-2-activating complex with role in G2/M checkpoint maintenance. Cell 136: 508-520.
207. Shin MS, Kim HS, Kang CS, Park WS, Kim SY, Lee SN, Lee JH, Park JY, Jang JJ, Kim CW, et al. 2002. Inactivating mutations of CASP10 gene in non-Hodgkin lymphomas. Blood 99: 4094-4099.
208. Shiozaki EN, Chai J, Shi Y. 2002. Oligomerization and activation of caspase-9, induced by Apaf-1 CARD. Proc Natl Acad Sci 99: 4197-4202.
209. Shoham NG, Centola M, Mansfield E, Hull KM, Wood G, Wise CA, Kastner DL. 2003. Pyrin binds the PSTPIP1/ CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc Natl Acad Sci 100: 13501-13506.
210. Sidi S, Sanda T, Kennedy RD, Hagen AT, Jette CA, Hoffmans R, Pascual J, Imamura S, Kishi S, Amatruda JF, et al. 2008. Chk1 suppresses a caspase-2 apoptotic response to DNA damage that bypasses p53, Bcl-2, and caspase-3. Cell 133: 864-877.
211. So A, De Smedt T, Revaz S, Tschopp J. 2007. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 9: R28.
212. Soung YH, Lee JW, Kim HS, Park WS, Kim SY, Lee JH, Park JY, Cho YG, Kim CJ, Park YG, et al. 2003. Inactivating mutations of CASPASE-7 gene in human cancers. Oncogene 22: 8048-8052.
213. Soung YH, Lee JW, Kim SY, Park WS, Nam SW, Lee JY, Yoo NJ, Lee SH. 2004. Somatic mutations of CASP3 gene in human cancers. Hum Genet 115: 112-115.
214. Soung YH, Lee JW, Kim SY, Jang J, Park YG, Park WS, Nam SW, Lee JY, Yoo NJ, Lee SH. 2005a. CASPASE-8 gene is inactivated by somatic mutations in gastric carcinomas. Cancer Res 65: 815-821.
215. Soung YH, Lee JW, Kim SY, Sung YJ, Park WS, Nam SW, Kim SH, Lee JY, Yoo NJ, Lee SH. 2005b. Caspase-8 gene is frequently inactivated by the frameshift somatic mutation 1225_1226delTG in hepatocellular carcinomas. Oncogene 24: 141-147.
216. Soung YH, Jeong EG, Ahn CH, Kim SS, Song SY, Yoo NJ, Lee SH. 2008. Mutational analysis of caspase 1, 4, and 5 genes in common human cancers. Hum Pathol 39: 895-900.
217. Spencer SL, Gaudet S, Albeck JG, Burke JM, Sorger PK. 2009. Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis. Nature 459: 428-432.
218. Spranger J, Kroke A, Mohlig M, Hoffmann K, Bergmann MM, Ristow M, Boeing H, Pfeiffer AF. 2003. Inflammatory cytokines and the risk to develop type 2 diabetes: Results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 52: 812-817.
219. Sprick MR, Rieser E, Stahl H, Grosse-Wilde A, Weigand MA, Walczak H. 2002. Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8. EMBO J 21: 4520- 4530.
220. Stack JH, Beaumont K, Larsen PD, Straley KS, Henkel GW, Randle JC, Hoffman HM. 2005. IL-converting enzyme/ caspase-1 inhibitor VX-765 blocks the hypersensitive response to an inflammatory stimulus in monocytes from familial cold autoinflammatory syndrome patients. JImmunol 175: 2630-2634.
221. Steimle V, Otten LA, Zufferey M, Mach B. 1993. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). Cell 75: 135-146.
222. Straathof KC, Pule MA, Yotnda P, Dotti G, Vanin EF, Brenner MK, Heslop HE, Spencer DM, Rooney CM. 2005. An inducible caspase 9 safety switch for T-cell therapy. Blood 105: 4247-4254.
223. Straus SE, Sneller M, Lenardo MJ, Puck JM, Strober W. 1999. An inherited disorder of lymphocyte apoptosis: The autoimmune lymphoproliferative syndrome. Ann Intern Med 130: 591-601.
224. Stupack DG, Teitz T, Potter MD, Mikolon D, Houghton PJ, Kidd VJ, Lahti JM, Cheresh DA. 2006. Potentiation of neuroblastoma metastasis by loss of caspase-8. Nature 439: 95-99.
225. Sutterwala FS, Ogura Y, Szczepanik M, Lara-Tejero M, Lichtenberger GS, Grant EP, Bertin J, Coyle AJ, Galan JE, Askenase PW, et al. 2006. Critical role for NALP3/ CIAS1/Cryopyrin in innate and adaptive immunity through its regulation of caspase-1. Immunity 24: 317- 327.
226. Sutterwala FS, Mijares LA, Li L, Ogura Y, Kazmierczak BI, Flavell RA. 2007. Immune recognition of Pseudomonas aeruginosa mediated by the IPAF/NLRC4 inflammasome. J Exp Med 204: 3235-3245.
227. Suzuki T, Franchi L, Toma C, Ashida H, Ogawa M, Yoshikawa Y, Mimuro H, Inohara N, Sasakawa C, Nunez G. 2007. Differential regulation of caspase-1 activation, pyroptosis, and autophagy via Ipaf and ASC in Shigellainfected macrophages. PLoS Pathog 3: e111.
228. Taylor RC, Cullen SP, Martin SJ. 2008. Apoptosis: Controlled demolition at the cellular level. Nat Rev Mol Cell Biol 9: 231-241.
229. Teitz T, Wei T, Valentine MB, Vanin EF, Grenet J, Valentine VA, Behm FG, Look AT, Lahti JM, Kidd VJ. 2000. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 6: 529-535.
230. Terkeltaub R, Sundy JS, Schumacher HR, Murphy F, Bookbinder S, Biedermann S, Wu R, Mellis S, Radin A. 2009. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: Results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann Rheum Dis 68: 1613-1617.
231. Tey SK, Dotti G, Rooney CM, Heslop HE, Brenner MK. 2007. Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol Blood Marrow Transplant 13: 913-924.
232. Thomas PG, Dash P, Aldridge JR Jr, Ellebedy AH, Reynolds C, Funk AJ, Martin WJ, Lamkanfi M, Webby RJ, Boyd KL, et al. 2009. The intracellular sensor NLRP3 mediates key innate and healing responses to influenza A virus via the regulation of caspase-1. Immunity 30: 566-575.
233. Tinel A, Tschopp J. 2004. The PIDDosome, a protein complex implicated in activation of caspase-2 in response to genotoxic stress. Science 304: 843-846.
234. Ting JP, Lovering RC, Alnemri ES, Bertin J, Boss JM, Davis BK, Flavell RA, Girardin SE, Godzik A, Harton JA, et al. 2008a. The NLR gene family: A standard nomenclature. Immunity 28: 285-287.
235. Ting JP, Willingham SB, Bergstralh DT. 2008b. NLRs at the intersection of cell death and immunity. Nat Rev Immunol 8: 372-379.
236. Tschopp J. 2011. Mitochondria: Sovereign of inflammation? Eur J Immunol 41: 1196-1202.
237. Tschopp J, Martinon F, Burns K. 2003. NALPs: A novel protein family involved in inflammation. Nat Rev Mol Cell Biol 4: 95-104.
238. Tu S, McStay GP, Boucher LM, Mak T, Beere HM, Green DR. 2006. In situ trapping of activated initiator caspases reveals a role for caspase-2 in heat shock-induced apoptosis. Nat Cell Biol 8: 72-77.
239. van der Meer JW, Vossen JM, Radl J, van Nieuwkoop JA, Meyer CJ, Lobatto S, van Furth R. 1984. Hyperimmunoglobulinaemia D and periodic fever: A new syndrome. Lancet 1: 1087-1090.
240. Varfolomeev EE, Schuchmann M, Luria V, Chiannilkulchai N, Beckmann JS, Mett IL, Rebrikov D, Brodianski VM, Kemper OC, Kollet O, et al. 1998. Targeted disruption of the mouse Caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apo1, and DR3 and is lethal prenatally. Immunity 9: 267-276.
241. Vogler M, Dinsdale D, Dyer MJ, Cohen GM. 2009. Bcl-2 inhibitors: Small molecules with a big impact on cancer therapy. Cell Death Differ 16: 360-367.
242. Wang L, Miura M, Bergeron L, Zhu H, Yuan J. 1994. Ich-1, an Ice/ced-3-related gene, encodes both positive and negative regulators of programmed cell death. Cell 78: 739-750.
243. Wang S, Miura M, Jung YK, Zhu H, Li E, Yuan J. 1998. Murine caspase-11, an ICE-interacting protease, is essential for the activation of ICE. Cell 92: 501-509.
244. Wang J, Zheng L, Lobito A, Chan FK, Dale J, Sneller M, Yao X, Puck JM, Straus SE, Lenardo MJ. 1999. Inherited human Caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II. Cell 98: 47-58.
245. Watanabe H, Gaide O, Petrilli V, Martinon F, Contassot E, Roques S, Kummer JA, Tschopp J, French LE. 2007. Activation of the IL-1β-processing inflammasome is involved in contact hypersensitivity. J Invest Dermatol 127: 1956-1963.
246. Wewers MD, Herzyk DJ. 1989. Alveolar macrophages differ from blood monocytes in human IL-1β release. Quantitation by enzyme-linked immunoassay. J Immunol 143: 1635-1641.
247. Wise CA, Gillum JD, Seidman CE, Lindor NM, Veile R, Bashiardes S, Lovett M. 2002. Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder. Hum Mol Genet 11: 961-969.
248. Woo M, Hakem R, Soengas MS, Duncan GS, Shahinian A, Kagi D, Hakem A, McCurrach M, Khoo W, Kaufman SA, et al. 1998. Essential contribution of caspase 3/CPP32 to apoptosis and its associated nuclear changes. Genes Dev 12: 806-819.
249. Woo M, Hakem R, Furlonger C, Hakem A, Duncan GS, Sasaki T, Bouchard D, Lu L, Wu GE, Paige CJ, et al. 2003. Caspase-3 regulates cell cycle in B cells: A consequence of substrate specificity. Nat Immunol 4: 1016- 1022.
250. Xu HL, Xu WH, Cai Q, Feng M, Long J, Zheng W, Xiang YB, Shu XO. 2009. Polymorphisms and haplotypes in the caspase-3, caspase-7, and caspase-8 genes and risk for endometrial cancer: A population-based, case-control study in a Chinese population. Cancer Epidemiol Biomarkers Prev 18: 2114-2122.
251. Xue Y, Daly A, Yngvadottir B, Liu M, Coop G, Kim Y, Sabeti P, Chen Y, Stalker J, Huckle E, et al. 2006. Spread of an inactive form of caspase-12 in humans is due to recent positive selection. Am J Hum Genet 78: 659-670.
252. Yamasaki K, Muto J, Taylor KR, Cogen AL, Audish D, Bertin J, Grant EP, Coyle AJ, Misaghi A, Hoffman HM, et al. 2009. NLRP3/cryopyrin is necessary for interleukin-1β (IL-1β) release in response to hyaluronan, an endogenous trigger of inflammation in response to injury. J Biol Chem 284: 12762-12771.
253. Yang GY, Schielke GP, Gong C, Mao Y, Ge HL, Liu XH, Betz AL. 1999. Expression of tumor necrosis factor-α and intercellular adhesion molecule-1 after focal cerebral ischemia in interleukin-1β converting enzyme deficient mice. J Cereb Blood Flow Metab 19: 1109-1117.
254. Yang X, Merchant MS, Romero ME, Tsokos M, Wexler LH, Kontny U, Mackall CL, Thiele CJ. 2003. Induction of caspase 8 by interferon {hooked} renders some neuroblastoma (NB) cells sensitive to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but reveals that a lack of membrane TR1/TR2 also contributes to TRAIL resistance in NB. Cancer Res 63: 1122-1129.
255. Yeh WC, Pompa JL, McCurrach ME, Shu HB, Elia AJ, Shahinian A, Ng M, Wakeham A, Khoo W, Mitchell K, et al. 1998. FADD: Essential for embryo development and signaling from some, but not all, inducers of apoptosis. Science 279: 1954-1958.
256. Yeh WC, Itie A, Elia AJ, Ng M, Shu HB, Wakeham A, Mirtsos C, Suzuki N, Bonnard M, Goeddel DV, et al. 2000. Requirement for Casper (c-FLIP) in regulation of death receptor-induced apoptosis and embryonic development. Immunity 12: 633-642.
257. Yin M, Yan J, Wei S, Wei Q. 2010. CASP8 polymorphisms contribute to cancer susceptibility: Evidence from a meta-analysis of 23 publications with 55 individual studies. Carcinogenesis 31: 850-857.
258. Ying Lu G-QC. 2011. Effector Caspases and Leukemia. Int J Cell Biol 2011. doi: 10.1155/2011/738301
259. Yoo NJ, Lee JW, Kim YJ, Soung YH, Kim SY, Nam SW, Park WS, Lee JY, Lee SH. 2004. Loss of caspase-2, -6 and -7 expression in gastric cancers. APMIS 112: 330-335.
260. Yoshida H, Kong YY, Yoshida R, Elia AJ, Hakem A, Hakem R, Penninger JM, Mak TW. 1998. Apaf1 is required for mitochondrial pathways of apoptosis and brain development. Cell 94: 739-750.
261. Yu JW, Wu J, Zhang Z, Datta P, Ibrahimi I, Taniguchi S, Sagara J, Fernandes-Alnemri T, Alnemri ES. 2006. Cryopyrin and pyrin activate caspase-1, but not NF-kB, via ASC oligomerization. Cell Death Differ 13: 236-249.
262. Zhang J, Cado D, Chen A, Kabra NH, Winoto A. 1998. Fasmediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/Mort1. Nature 392: 296-300.
263. Zhang WH, Wang X, Narayanan M, Zhang Y, Huo C, Reed JC, Friedlander RM. 2003. Fundamental role of the Rip2/caspase-1 pathway in hypoxia and ischemiainduced neuronal cell death. Proc Natl Acad Sci 100: 16012-16017.
264. Zhang HZ, Kasibhatla S, Wang Y, Herich J, Guastella J, Tseng B, Drewe J, Cai SX. 2004. Discovery, characterization and SAR of gambogic acid as a potent apoptosis inducer by a HTS assay. Bioorg Med Chem 12: 309-317.
265. Zhang H, Zhou X, McQuade T, Li J, Chan FK, Zhang J. 2011. Functional complementation between FADD and RIP1 in embryos and lymphocytes. Nature 471: 373-376.
266. Zheng TS, Hunot S, Kuida K, Flavell RA. 1999. Caspase knockouts: Matters of life and death. Cell Death Differ 6: 1043-1053.